milrinone has been researched along with alprostadil in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoffmann, A; Klöcking, HP | 1 |
| Bonnet, PA; Chevillard, C; Michel, A; Vittet, D; Zurbonsen, K | 1 |
| Heintz, B; Kirsten, D; Kirsten, R; Nelson, K | 1 |
| Bivalacqua, TJ; Champion, HC; Doherty, PC; Hellstrom, WJ; Kadowitz, PJ; Rajasekaran, M; Sikka, SC | 1 |
| Ikeda, T; Kazama, T; Kikura, M; Sato, S | 1 |
| Awad, H; Michler, RE; Stobierska-Dzierzek, B | 1 |
2 review(s) available for milrinone and alprostadil
| Article | Year |
|---|---|
Clinical pharmacokinetics of vasodilators. Part II.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Agonists; Alprostadil; Amrinone; Carbazoles; Carvedilol; Enoximone; Female; Humans; Iloprost; Imidazoles; Indoramin; Isosorbide Dinitrate; Labetalol; Milrinone; Molsidomine; Nitroglycerin; Nitroprusside; Oxyfedrine; Pentaerythritol Tetranitrate; Phosphodiesterase Inhibitors; Piperazines; Prazosin; Pregnancy; Propanolamines; Pyridones; Theophylline; Trapidil; Vasodilator Agents | 1998 |
The evolving management of acute right-sided heart failure in cardiac transplant recipients.
Topics: Alprostadil; Animals; Cardiotonic Agents; Epoprostenol; Heart Transplantation; Heart-Assist Devices; Hemodynamics; Humans; Hypertension, Pulmonary; Milrinone; Nitric Oxide; Phosphodiesterase Inhibitors; Risk Factors; Vasodilator Agents; Ventricular Dysfunction, Right | 2001 |
4 other study(ies) available for milrinone and alprostadil
| Article | Year |
|---|---|
Inhibition of thrombin-induced tissue-type plasminogen activator release by agents which increase intracellular cyclic AMP.
Topics: 1-Methyl-3-isobutylxanthine; Alprostadil; Animals; Colforsin; Cyclic AMP; Ear, External; In Vitro Techniques; Milrinone; Perfusion; Phosphodiesterase Inhibitors; Pyridazines; Pyridones; Solutions; Swine; Thrombin; Tissue Plasminogen Activator | 1990 |
Dissociation between phosphodiesterase inhibition and antiproliferative effects of phosphodiesterase inhibitors on the Dami cell line.
Topics: 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Alprostadil; Cell Division; Cyclic AMP; Humans; Isoenzymes; Isoquinolines; L-Lactate Dehydrogenase; Leukemia, Megakaryoblastic, Acute; Milrinone; Phosphodiesterase Inhibitors; Phthalazines; Pyridones; Pyrrolidinones; Rolipram; Tetrahydroisoquinolines; Tumor Cells, Cultured | 1997 |
Potentiation of erectile response and cAMP accumulation by combination of prostaglandin E1 and rolipram, a selective inhibitor of the type 4 phosphodiesterase (PDE 4).
Topics: Alprostadil; Animals; Cats; Cells, Cultured; Cyclic AMP; Cyclic GMP; Dose-Response Relationship, Drug; Male; Milrinone; Penile Erection; Penis; Phosphodiesterase Inhibitors; Purinones; Rolipram | 1999 |
Disaggregatory effects of prostaglandin E1, amrinone and milrinone on platelet aggregation in human whole blood.
Topics: Adenosine Diphosphate; Adult; Alprostadil; Amrinone; Cardiotonic Agents; Collagen; Cyclic AMP; Dose-Response Relationship, Drug; Electrochemistry; Humans; Kinetics; Male; Middle Aged; Milrinone; Platelet Aggregation; Platelet Aggregation Inhibitors; Vasodilator Agents | 2000 |